2022 World Conference on Lung Cancer (ePosters)-EP08.02-169. Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation

EP08.02-169. Research of Aumolertinib Combined with Bevacizumab for Advanced NSCLC Lung Cancer with EGFR Sensitive Mutation

Back to course

Pdf Summary

A study was conducted to evaluate the combination of aumolertinib (HS-10296) and bevacizumab for untreated patients with advanced non-squamous and non-small-cell lung cancer (NS-NSCLC) with EGFR sensitive mutations. The primary endpoint of the study was progression-free survival (PFS) at 12 months, and secondary endpoints included objective response rate (ORR), overall survival (OS), and safety.<br /><br />The study included 19 patients with a median follow-up of 9.3 months. The median PFS was not reached, indicating promising results for the combination therapy. The best response rate was evaluated in 15 patients, with an ORR of 66.7% and a disease control rate (DCR) of 93.3%. The average reduction in intracranial target lesions was 37.0%, demonstrating the efficacy of the treatment for patients with central nervous system (CNS) metastases.<br /><br />In terms of safety, the combination therapy showed manageable toxicities. Adverse events reported included leukopenia, rash, pruritus, anorexia, constipation, fatigue, albuminuria, stomatitis, toothache, oral bleeding, chest pain, myalgia, AST/ALT increase, and creatine kinase increase. Three patients experienced grade 3 adverse events, and one patient discontinued bevacizumab due to chest pain.<br /><br />Overall, the study concluded that the combination of aumolertinib and bevacizumab exhibited superior activity and manageable toxicities for advanced EGFR-mutated NS-NSCLC, particularly in patients with CNS metastases and co-occurring gene alterations like TP53. It suggests that this combination therapy may be a new and effective strategy for these patients, but further large-scale randomized controlled trials are still needed to confirm these findings.

Asset Subtitle

Dian Sheng Zhong

Meta Tag

Speaker Dian Sheng Zhong

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

aumolertinib

bevacizumab

NS-NSCLC

EGFR sensitive mutations

progression-free survival

objective response rate

safety

CNS metastases

adverse events

gene alterations